London
· Delayed Price · Currency is GBP · Price in USD 10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of GBP 738.46 million. The enterprise value is 504.48 million.
| Market Cap | 738.46M |
| Enterprise Value | 504.48M |
Important Dates
The next estimated earnings date is Friday, May 2, 2025.
| Earnings Date | May 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.80% |
| Shares Change (QoQ) | +0.72% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 106.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.51 |
| PB Ratio | 1.30 |
| P/TBV Ratio | 1.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 138.73 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.46 |
| EV / Sales | 1.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -110.24 |
Financial Position
The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.97 |
| Quick Ratio | 4.09 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | -14.42 |
| Interest Coverage | -48,115.95 |
Financial Efficiency
Return on equity (ROE) is -25.17% and return on invested capital (ROIC) is -14.77%.
| Return on Equity (ROE) | -25.17% |
| Return on Assets (ROA) | -12.77% |
| Return on Invested Capital (ROIC) | -14.77% |
| Return on Capital Employed (ROCE) | -24.03% |
| Revenue Per Employee | 373,566 |
| Profits Per Employee | -111,698 |
| Employee Count | 1,306 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.50 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.97% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -71.97% |
| 50-Day Moving Average | 10.01 |
| 200-Day Moving Average | 15.78 |
| Relative Strength Index (RSI) | 42.97 |
| Average Volume (20 Days) | 3,441 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.63 |
Income Statement
In the last 12 months, 10x Genomics had revenue of GBP 487.88 million and -145.88 million in losses. Loss per share was -1.21.
| Revenue | 487.88M |
| Gross Profit | 331.32M |
| Operating Income | -153.73M |
| Pretax Income | -141.94M |
| Net Income | -145.88M |
| EBITDA | -125.07M |
| EBIT | -153.73M |
| Loss Per Share | -1.21 |
Balance Sheet
The company has 314.24 million in cash and 65.99 million in debt, giving a net cash position of 248.25 million.
| Cash & Cash Equivalents | 314.24M |
| Total Debt | 65.99M |
| Net Cash | 248.25M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 567.23M |
| Book Value Per Share | 4.64 |
| Working Capital | 372.83M |
Cash Flow
In the last 12 months, operating cash flow was 5.32 million and capital expenditures -9.90 million, giving a free cash flow of -4.58 million.
| Operating Cash Flow | 5.32M |
| Capital Expenditures | -9.90M |
| Free Cash Flow | -4.58M |
| FCF Per Share | n/a |
Margins
Gross margin is 67.91%, with operating and profit margins of -31.51% and -29.90%.
| Gross Margin | 67.91% |
| Operating Margin | -31.51% |
| Pretax Margin | -29.09% |
| Profit Margin | -29.90% |
| EBITDA Margin | -25.64% |
| EBIT Margin | -31.51% |
| FCF Margin | n/a |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.80% |
| Shareholder Yield | -2.80% |
| Earnings Yield | -19.75% |
| FCF Yield | -0.62% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 7.44.
| Altman Z-Score | 7.44 |
| Piotroski F-Score | n/a |